Clinical Trial

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

Study acronym: RESOLVE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.
Protocol Amendment History 37 amendments
This ClinicalTrials.gov record has been amended 37 times since 2016-07-05; most recent amendment 2025-04-01.
Status change: Not Yet Recruiting → Recruiting 2016-07-20
Trial Details
NCT Number NCT02823821
Lead Sponsor University of Sydney
Collaborators: Australasian Kidney Trials Network, Australia & New Zealand Dialysis & Transplant Registry, The George Institute, The George Institute for Global Health, China, Peking University People's Hospital, Institute for Clinical Evaluative Sciences, St. Michaels Hospital, Wuerzburg University Hospital, Malaysian Society of Nephrology, Malaysian Renal Registry, University College, London
Conditions End-Stage Kidney Disease
Enrollment 50,000 participants
Start Date 2016-06
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-04